Qulipta 10 mg tablet is a prescription medicine containing Atogepant for oral use, marketed by AbbVie, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store between 20°C and 25°C (68°F and 77°F): excursions permitted between 15°C…
Key facts
- Active ingredient (INN)
- Atogepant
- Brand
- Qulipta
- Strength
- 10 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets
- Marketing authorisation holder
- AbbVie
- Manufacturer
- AbbVie
- Origin register
- US FDA, United States
- Storage
- Store between 20°C and 25°C (68°F and 77°F): excursions permitted between 15°C and 30°C (59°F and 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N02CD07 Atogepant
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 30 September 2021
- Identifiers
- RxCUI 2571836, 2571842, 2571844 +3DailyMed set ID 8c8ab8f4-32bd-497a-befa-70c8a51d8d52NDC 0074-7095Application NDA215206
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet in 1 bottle | 0074-7095-30 | AbbVie | 30 September 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Atogepant
Clinical summary
Atogepant is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults. It is available as tablets for oral use. MedsAcross supplies Atogepant for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AtogepantFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Qulipta prescribing information (AbbVie) · U.S. National Library of Medicine, DailyMed
- Aquipta: European public assessment report (EPAR) · European Medicines Agency
Need Qulipta 10 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.